logo
Sign in

0HB0 Stock Price, Chart, Stats & News

Agios Pharmaceuticals, Inc.
Save

Agios Pharmaceuticals, Inc. (0HB0) does not currently pay a dividend.

1.93B
Market cap
–
Current P/E
–
Forward P/E

0HB0 chart

About

Health care
Sector
Biotechnology
Industry

Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions.

Similar securities

Based on sector and market capitalization

Report issue